Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Showing results (161-170 of 273) with videos related to

Pageof 28
Sort By:
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.
The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.
Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Blood Advances|August 13, 2021
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L Crombie, Amy C Sherman, Chi-An Cheng, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Blood|February 3, 2017
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapyTakeru Asano, Yusuke Meguri, Takanori Yoshioka, et al.
Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Pageof 28

Showing results (161-170 of 273) with videos related to

Sort By:
Pageof 28
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.
The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.
Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Blood Advances|August 13, 2021
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L Crombie, Amy C Sherman, Chi-An Cheng, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Blood|February 3, 2017
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapyTakeru Asano, Yusuke Meguri, Takanori Yoshioka, et al.
Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Blood Advances|March 26, 2026
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter TransformationJennifer L Crombie, Christine E Ryan, Yue Ren, et al.
Pageof 28